|
Found 89 result(s) FROM 1963 pages containing the term 'ankylosing spondylitis'.
Tuesday Nov 03, 2009
Naproxen/Nexium Combo Prevents Ulcers in OA Patients
Combining naproxen esomeprazole magnesium relieves OA pain while protecting the stomach...
Tuesday Oct 06, 2009
Simponi Scores EU OK for RA, PsA, AS
Simponi (golimumab) anti-TNF is the first monthly anti-TNF injectable to gain broad EU approval...
Thursday Jul 16, 2009
Array BioPharma Stops Work on ARRY-797 Pan-Cytokine Inhibitor for RA Despite Good Early Data
The pan-cytokine inhibitor ARRY-797 was safe at doses of up to 1,200 mg/day in a phase 1 dose-escalation study in RA patients, but will not be developed further for use in RA...
Thursday Jun 25, 2009
From Inflammation to Bone Formation in SpA
Clinical and animal data reported at EULAR suggest that both controlling inflammation and preventing new bone formation may be required to stop ankylosing spondylitis progression...
Friday May 22, 2009
Johnson & Johnson Wants Remicade Back
J&J is going to court to end its Remicade partnership with Schering-Plough due to a merger with Merck...
Wednesday Apr 29, 2009
Simponi Approved in US for RA, PsA, AS
The US Food and Drug Administration this week joined Canada's drugs agency in approving Simponi (golimumab) for moderate to severe RA, active PsA, and active ankylosing spondylitis...
Tuesday Apr 14, 2009
Golimumab Gets Canadian OK for RA, PsA, AS
Health Canada has approved Centocor's Simponi (golimumab) for treatment of moderately to severely active rheumatoid arthritis (RA), active psoriatic arthritis (PsA), and active ankylosing spondylitis (AS)...
Tuesday Apr 07, 2009
Low Back, Limb Pain May Be Early Spondyloarthritis
Low back pain, sacroiliitis, and limb arthritis are all early signs of spondyloarthritis...
Tuesday Nov 18, 2008
Centocor's Golimumab Gives Durable Skin, Joint Relief in Psoriatic Arthritis, ACR Studies Say
More than half of active psoriatic arthritis patients receiving subcutaneous injections of 50 mg or 100 mg of golimumab (CNTO 148) every 4 weeks showed improvements that lasted through 1 year in the joint and skin symptoms...
Friday Nov 07, 2008
Studies Confirm, Extend Uses of MRI in Spondyloarthropathies
Severe romanus lesions in patients with back pain who are younger than 51 are very specific for spondyloarthropathy, and an MRI of just the sacroiliac joint is generally enough to diagnose nonradiographic axial SpA, regardless of the location of the back pain...
Monday Sep 29, 2008
Abbott Reports Continuous Treatment With Humira® Achieves Superior Long-Term Efficacy for Psoriasis Patients in the US and Europe Versus Interrupting Treatment
The findings were from the company's pivotal 52-week REVEAL study and the period of open-label treatment that followed...
Monday Sep 08, 2008
ACR Research and Education Foundation Grants Point to New Arthritis Research
New REF grants target RA immunotherapy, inflammation, bone erosions, PAD inhibition...
Thursday Jul 31, 2008
Antidepressants Pass Analgesic Muster for Fibromyalgia, Chronic Back Pain
Antidepressants can relieve the pain associated with some rheumatic conditions including fibromyalgia and chronic low back pain, but they may not have such pain-killing effects in other related diseases…
Tuesday Jul 15, 2008
Wyeth Reports European Commission Announces Marketing Authorization for 50 mg Once-Weekly Enbrel® (etanercept) for Patients With Moderate-to-Severe Psoriasis
The European Commission announced a new 50 mg Enbrel® (etanercept) once-weekly dosage regimen as an alternative to the currently approved 25 mg Enbrel twice-weekly regimen for the treatment of moderate-to-severe plaque psoriasis...
Wednesday Jul 09, 2008
Lasting Leukemia Risk for AS Patients Treated With Now Banned 224Radium (SpondylAT®)
AS patients who were treated with repeated intravenous injections of 224Radium (SpondylAT®) are at increased risk for developing leukemia…
Thursday Jul 03, 2008
Centocor Requests Approval From FDA of Golimumab for the Treatment of RA, Psoriatic Arthritis, and Ankylosing Spondylitis
Centocor submitted a Biologics License Application to the US FDA requesting the approval of golimumab, a human anti-TNFα monoclonal antibody, as a monthly subcutaneous treatment for adults with active forms of RA, PsA, and AS...
Friday May 16, 2008
Centocor Alerts Authorized Distributors and Prescribing Physicians About Stolen Infliximab (Remicade®)
A transport trailer carrying infliximab (Remicade®) was stolen en route to a specialty distributor on May 6, 2008...
Monday Apr 21, 2008
Abbott’s Humira® (adalimumab) Approved in Japan for the Treatment of RA
Abbott received approval in Japan for Humira® (adalimumab) to treat RA in patients with inadequate response to conventional therapy...
Tuesday Apr 08, 2008
Does Physical Therapy Still Have a Place in the Treatment of Ankylosing Spondylitis?
Researchers believe that pharmacological advancements in the treatment of ankylosing spondylitis do not replace traditional physical therapy programs…
Tuesday Mar 25, 2008
Yeast Antibodies Predict More Severe AS
Patients with seronegative spondyloarthropathies, especially AS, who have high levels of antibodies to Saccharomyces cerevisiae are likely to have more severe disease and to need more anti-TNF therapy...
Tuesday Mar 25, 2008
Diagnosis Delay in Patients with Ankylosing Spondylitis
Researchers have established new diagnostic criteria for ankylosing spondylitis in an effort to minimize the diagnosis delay in AS...
Wednesday Mar 19, 2008
Centocor, Schering-Plough Submit Marketing Authorization Application Requesting EU Approval of Golimumab to Treat RA, PsA, AS
Centocor, Inc and Schering-Plough Corp are seeking EU approval of golimumab, which targets and neutralizes both the soluble and membrane-bound forms of TNFα, to treat RA, PsA, and AS...
Friday Feb 08, 2008
TNF Inhibitors, Efalizumab, Alefacept Herald New Era in Psoriasis Treatment
New treatment strategies that include TNF-α inhibitors, efalizumab, and alefacept offer better psoriasis control with less toxicity, but still need to be compared with traditional agents in clinical trials...
Wednesday Jan 23, 2008
Abbott's Humira® Approved in US for Treatment of Moderate-to-Severe Chronic Plaque Psoriasis
Abbott Laboratories announced it has received US FDA approval to market Humira® (adalimumab) for adults with moderate-to-severe chronic plaque psoriasis...
Tuesday Jan 15, 2008
Three More Cases of Significant Neutropenia Lead to Recommendation for Routine CBC Monitoring
Three more cases of significant neutropenia in rheumatoid arthritis (RA) and psoriatic arthritis patients treated with etanercept lead to a recommendation for regular monitoring of complete blood counts (CBC)...
Tuesday Jan 15, 2008
Evaluation of a Quantitative Scoring of Enthesitis in Ankylosing Spondylitis
Researchers assessed the validity of an enthesitis index calculated by algometric pressure pain threshold scoring...
Monday Jan 07, 2008
Abbott's Humira® Approved in the EU for Treatment of Moderate-to-Severe Plaque Psoriasis
Abbott announced it has received marketing authorization from the European Commission for the use of the TNF antagonist Humira® (adalimumab) as a treatment for moderate-to-severe plaque psoriasis. Humira is the first fully human, self-injectable biologic for the treatment of psoriasis...
Tuesday Dec 11, 2007
Identification of Two New Ankylosing Spondylitis Genes Suggest Novel Therapeutic Targets
Genome scans have identified two of the suspected handful of non-MHC genes that appear to collaborate with HLA-B27 in "turning on" disease processes that result in ankylosing spondylitis and other seronegative arthropathies...
Wednesday Dec 05, 2007
Drug Update: Infliximab
Researchers offer advice on reducing infliximab infusion times in RA, predicting who will respond, and what to expect in patients with ankylosing spondylitis...
Thursday Nov 08, 2007
Centocor, Schering-Plough's Anti-TNF Golimumab Significantly Improved Articular, Skin, and Nail Manifestations in Patients With Psoriatic Arthritis in Phase III Study; Met Primary and Major Secondary Endpoints
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that patients with active psoriatic arthritis (PsA) receiving monthly subcutaneous injections of golimumab experienced significant and sustained improvements in the joint and skin manifestations of the disease, according to findings from the largest phase III biologic study (GO-REVEAL trial) in PsA subjects...
Thursday Nov 08, 2007
Centocor, Schering-Plough's Anti-TNF Golimumab Significantly Reduced Signs and Symptoms of AS in Phase III Study; Monthly Treatment Yielded Marked Improvements in Physical Function
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson, announced that more than half of patients receiving monthly subcutaneous injections of golimumab 50 mg and 100 mg experienced significant and sustained improvements in the signs and symptoms of active ankylosing spondylitis (AS), according to the phase III study (GO-RAISE trial) results...
Thursday Oct 11, 2007
Review Rejects "Chronic Lyme Disease" Diagnosis, Extended IV Antibiotics
A major review challenges "chronic Lyme disease" as a valid diagnosis and warns against extended use of IV antibiotics...
Thursday Sep 27, 2007
Panel Issues New Guidelines for Use of Imaging in Ankylosing Spondylitis
Although standard X-rays are essential for diagnosis and MRI may help diagnose early cases before radiographic damage develops, no form of imaging is yet useful for monitoring response to treatment or for routine monitoring of disease progression in AS, experts say...
Friday Sep 21, 2007
TNF Blockade Slows But Does Not Stop X-Ray Progression in AS
Four-year follow-up data show that infliximab slows but does not inhibit radiographic progression in AS…
Tuesday Aug 28, 2007
Systematic Review Finds No Benefit From Selenium or Vitamins A, C in Arthritis; Raises Methodological Questions About Studies Showing Benefit From Vitamin E
Antioxidant vitamins A, C, and E, sometimes combined with selenium, have been widely touted as beneficial for the treatment of arthritis, but a systematic review finds little convincing evidence of efficacy...
Wednesday Jun 13, 2007
Stopping AS May Require Earlier Use of TNF-Inhibitors
Inflammation in AS stops once the subchondral bone is eroded and the bone/cartilage interface disappears, so preventing bone erosion and syndesmophyte formation is likely to require early anti-inflammatory treatment, including TNF-inhibitors...
Monday Jun 11, 2007
Centocor's Remicade® (Infliximab) Receives EU Approval as First and Only Biologic for the Treatment of Pediatric Patients With Severe, Active Crohn's Disease
Centocor, Inc, a wholly owned subsidiary of Johnson & Johnson and Schering-Plough Corp, announced that the European Commission has approved a new indication for Remicade (infliximab) allowing for the treatment of severe, active Crohn's disease (CD) in pediatric patients ages 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator, and primary nutrition therapy, or who are intolerant to, or have contraindications for such therapies...
Monday Jun 11, 2007
Abbott's HUMIRA® (Adalimumab) Approved in the European Union for the Treatment of Crohn's Disease
Abbott Laboratories announced that it has received marketing authorization from the European Commission for the use of Humira® (adalimumab) as a treatment for severe Crohn's disease (CD)...
Tuesday Jun 05, 2007
Peptech's Anti-TNF Domain Antibody (PN0621) Enters Phase I Clinical Trial
Peptech Limited, is a clinical-stage biopharmaceutical company dedicated to developing and providing antibody- and peptide-based human therapeutic products for the treatment of inflammatory diseases and cancer...
Monday Apr 16, 2007
Abbott Seeks US and EU Regulatory Approval for HUMIRA® (Adalimumab) in Psoriasis; Receives US FDA Approval in Crohn's Disease
Abbott Laboratories announced that it has simultaneously submitted a supplemental Biologics License Application (sBLA) with the US FDA and a Type II Variation to the European Medicines Agency (EMEA) seeking approval to market HUMIRA® (adalimumab) as a treatment for moderate-to-severe chronic plaque psoriasis, the fifth autoimmune disease targeted for HUMIRA therapy in both the US and Europe...
Monday Apr 09, 2007
Study on Link Between RA and Diabetes Leaves Many Questions Unanswered
Some research has suggested an inflammation-mediated link between RA and diabetes, but a new study may debunk this theory...
Wednesday Feb 28, 2007
Abbott's HumiraR (Adalimumab) Receives FDA Approval for Self-Administered Treatment of Moderate-to-Severe Crohn's Disease; Represents 4th FDA Approval in Immune-Mediated Diseases for Humira
Abbott announced it has received US FDA approval to market Humira® (adalimumab, a fully human anti-TNF-α monoclonal antibody) as a treatment for reducing the signs and symptoms and inducing and maintaining clinical remission of moderately-to-severely active Crohn's disease (CD) in adults who have had an inadequate response to conventional therapy...
Thursday Jan 25, 2007
Anti-Infliximab Antibodies Linked to Nonresponse in AS
New research outlines some drawbacks and limitations in the use of TNF-inhibitors among patients with ankylosing spondylitis (AS) and other forms of spondylarthritis...
Thursday Jan 25, 2007
TNF Inhibitors May Protect Against Several Types of RA Cardiovascular Risk
RA patients treated with TNF inhibitors might also gain some protection against CV morbidity and mortality...
Thursday Jan 18, 2007
New Treatments Rocked Rheumatology in 2006
New treatment options have advanced rheumatology care in 2006, but lupus remains an unsolved problem, and CIAOMed Editorial Board members expect economic issues to greatly impact rheumatology practice in 2007...
Wednesday Dec 06, 2006
Serum MMP-3 May Be Biomarker of Joint Damage in AS, MRI Accuracy Questioned
Measuring serum levels of metalloproteinase 3 (MMP3) may be an inexpensive yet accurate way for rheumatologists to predict which AS patients will develop joint damage, particularly in those with pre-existing radiographic damage...
Thursday Nov 16, 2006
Abbott's HUMIRA (adalimumab) Approved in Canada for Treatment of Ankylosing Spondylitis
Abbott announced that it has received approval from Health Canada to market HumiraR (adalimumab) as a treatment for active ankylosing spondylitis (AS) in Canada.
Tuesday Nov 07, 2006
Study IDs Predictors of Poor Outcome in Enthesitis-Related Arthritis
Enthesitis-related arthritis (ERA) patients tend to have worse outcomes than children with other subtypes of juvenile idiopathic arthritis (JIA). Predictors of poor outcome include family history of related diseases, the presence of HLA-DRB1*08, the absence of a protective HLA subtype, and persistently elevated erythrocyte sedimentation rate (ESR)…
Thursday Oct 19, 2006
Access to TNF-Blockers Severely Limited in UK
Access to TNF-inhibitor treatment is limited even for British RA patients who meet official guidelines for treatment, and is even more limited for patients with psoriatic arthritis or ankylosing spondylitis ... Kay, LJ, et al. Rheumatology. 2006 Oct 11; [Epub ahead of print].
Monday Sep 11, 2006
Abbott Seeks US and EU Approvals for HUMIRA (Adalimumab) for Crohn's Disease
Abbott announced it has simultaneously submitted a supplemental Biologics License Application with the US FDA and a Type II Variation to the European Medicines Agency seeking approval to market HUMIRAR (adalimumab) as a treatment for moderate-to-severe Crohn's disease...
Wednesday Aug 23, 2006
Niche Use Seen for SSZ in Inflammatory Back Pain
SSZ may be useful in patients with inflammatory back pain who do not have peripheral arthritis... Braun J, et al. Ann Rheum Dis. 2006;65:1147-1153
Thursday Aug 17, 2006
Early Diagnosis of AS: Dr. Rudwaleit Does the Math to Make It Easy
Diagnosing early ankylosing spondylitis in a patient with chronic back pain may be easier with a simple method based on standard tests and symptoms... Rudwaleit M, et al. Ann Rheum Dis. 2006;65:1251-1252.
Tuesday Aug 01, 2006
Schering-Plough's REMICADE Receives EU Approval as Monotherapy for Treatment of Psoriatic Arthritis; Abbott's HUMIRA Receives FDA Approval for Treatment of Ankylosing Spondylitis
Schering-Plough Corporation announced that the European Commission approved the use of REMICADE® (infliximab) as monotherapy in the treatment of active and progressive psoriatic arthritis (PsA) in patients who show intolerance to methotrexate (MTX) or for whom MTX is contraindicated.
Monday Jun 12, 2006
Abbott's Humira® Approved in European Union for Severe Ankylosing Spondylitis
Abbott Laboratories announced that Humira® (adalimumab) was approved by the European Commission for marketing in Europe as a treatment for severe, active ankylosing spondylitis...
Monday Jun 05, 2006
PsA Enthesopathy As Cause of Plantar Fasciitis Responds to TNF Inhibitors
The TNF inhibitors infliximab and etanercept are both effective for the treatment of enthesopathy associated with psoriatic arthritis... Ritchlin CT. J Rheumatol. 15 May 2006; [Epub ahead of print]
Wednesday May 24, 2006
Centocor's RemicadeR Approved by US FDA for Pediatric Crohn's Disease
Centocor Inc announced US FDA approval of Remicade® (infliximab) for reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients with moderately to severely active Crohn's disease...
Monday May 15, 2006
Infliximab Cools Spinal Inflammation in AS
Six months of infliximab significantly reduced MRI-proven sites of spinal inflammation in patients with ankylosing spondylitis... Braun J, et al. Arthritis Rheum. 2006;54:1646-1652.
Monday May 01, 2006
Abbott's HumiraR (Adalimumab) Receives Positive Opinion From EMEA for Ankylosing Spondylitis
Abbott Laboratories, of Abbott Park, Illinois, announced that the Committee for Medicinal Products for Human Use (CHMP), of the European Medicines Agency (EMEA), issued a positive opinion recommending approval of Humira® (adalimumab)...
Tuesday Feb 14, 2006
Disease Activity and Severity Seen as Determinants in Starting Tumor Necrosis Factor-Alpha Blockers in Ankylosing Spondylitis Prior to Publication of ASAS Recommendations
Both disease activity and severity were determinants in starting tumor necrosis factor-alpha blockers in ankylosing spondylitis patients prior to the publication of the 2003 Assessment in AS (ASAS) international working group recommendations... Pham T, et al. Ann Rheum Dis [serial online]. February 7, 2006; doi:10.1136/ard.2005.042630
Monday Jan 30, 2006
Sales of Abbott's Humira® Exceed $1B in 2005
Abbott Laboratories reported that worldwide sales for Humira® (adalimumab) reached $1.4 billion...
Wednesday Jan 25, 2006
Targeted Genetics Restructures to Advance Anti-TNF-Alpha Agent tgAAC94 for Inflammatory Arthritis
Targeted Genetics Corporation, of Seattle, Washington, announced the restructuring of its operations...
Wednesday Nov 16, 2005
TNF-α Antagonist Adalimumab Shows Promise in AS
Encouraging results from the ATLAS trial suggest that adalimumab and other TNF-α inhibitors may be effective in reducing the signs and symptoms of ankylosing spondylitis... Presented at: Annual Meeting of the American College of Rheumatology; November 12–17, 2005; San Diego, Calif.
Wednesday Nov 02, 2005
Additional Encouraging Data from Targeted Genetics' Inflammatory Arthritis Program
The trial was designed to evaluate the safety of a single dose of tgAAC94...
Tuesday Oct 25, 2005
Combining X-Rays and MRIs Can Lead to Earlier Diagnosis of Spondyloarthritides
Combining data from X-rays and magnetic resonance imaging scans may lead to earlier detection of spondyloarthritides in patients presenting with recent-onset inflammatory back pain. Heuft-Dorenbosch L, et al. Ann Rheum Dis [serial online]. October 11, 2005.
Wednesday Oct 12, 2005
Centocor Obtains Approval in Europe for Remicade® for Psoriasis
Centocor, Inc, and its marketing partner, Schering-Plough Corporation, have announced that the European Commission has granted approval of RemicadeR (infliximab)...
Thursday Oct 06, 2005
Abbott's HumiraR (Adalimumab) Approved in Europe for Psoriatic Arthritis and Severe Rheumatoid Arthritis
Abbott Laboratories announced that it has received US Food and Drug Administration (FDA) approval to market HumiraR (adalimumab)...
Wednesday Sep 21, 2005
Johnson & Johnson's Remicade (infliximab) First Biologic Approved by US FDA for Treatment of Ulcerative Colitis
Centocor, Inc, a biotech unit of Johnson & Johnson, has announced that Remicade® (infliximab) has been approved by the US Food and Drug Administration...
Friday Sep 16, 2005
Neurochem Initiates Rolling NDA Submission for Fibrillexâ„¢ for AA Amyloidosis
Neurochem Inc announced that it has initiated submission of a rolling new drug application (NDA) to the US FDA seeking marketing approval for Fibrillexâ„¢...
Tuesday Aug 23, 2005
MRI Data Show Etanercept Reduces Spinal Lesions in AS, but Questions Remain
Etanercept therapy leads to the regression of spinal lesions in active ankylosing spondylitis and undifferentiated spondyloarthritis... Rudwaleit M, et al. Ann Rheum Dis. 2005;64:1305-1310
Tuesday Aug 09, 2005
FDA Approves Celebrex for Ankylosing Spondylitis, and an Added Boxed Warning
Pfizer's selective cyclo-oxygenase 2 (COX-2) inhibitor Celebrex (celecoxib) has been approved by the US Food and Drug Administration (FDA) for the relief of the clinical signs and symptoms associated with ankylosing spondylitis
Sunday Aug 07, 2005
Neurochem Initiates Submission of NDA With US FDA for Fibrillexâ„¢ in AA Amyloidosis
Neurochem has announced that it has initiated, under the Continuous Marketing Application Pilot 1 program...
Wednesday Jun 22, 2005
Early Ankylosing Spondylitis Cohort Underscores Link Between Sustained Disease Activity and Progression
German Spondyloarthritis Inception Cohort (GESPIC) shows that sustained high disease activity during the early stages of AS, despite treatment with NSAIDs, may be an important prognostic indicator of disease progression, and may suggest a possible earlier role for TNF-blockade... Presented at: European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Wednesday Jun 15, 2005
Etanercept Expands PsA Indication to Include Improvement of Physical Function
Amgen Inc and Wyeth Pharmaceuticals announced that the US Food and Drug Administration (FDA) expanded the marketing approval of Enbrel® (etanercept) to include the improvement of physical function in patients with psoriatic arthritis (PsA).
Monday Jun 13, 2005
EULAR Report: Developments in the Treatment of Ankylosing Spondylitis Using TNF-α Inhibitors
Studies of low-dose regimens, the effects of discontinuation, and 52-week data from an initial study of adalimumab highlight the results presented at EULAR on the use of TNF-α inhibitors in the treatment of AS...Presented at Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Friday Jun 10, 2005
EULAR Issues Treatment Recommendations for Early Arthritis, Ankylosing Spondylitis, and Gout
European rheumatologists released three new sets of recommendations for the management of early arthritis, ankylosing spondylitis (AS), and gout. Taken together the three sets of recommendations do not offer many specifics, but do chart at least an initial course of action for patients...Presented at: Annual European Congress of Rheumatology of EULAR; June 8-11, 2005; Vienna, Austria.
Monday Jun 06, 2005
Trials Outline Effective Strategies for the Use of Existing Therapies in Ankylosing Spondylitis
Four new studies highlight ways to use non-steroidals, biologics, and methotrexate in ankylosing spondylitis. Marzo-Ortega H, et al. Ann Rheum Dis. 2005 May 26; [Epub ahead of print].
Friday May 20, 2005
Study Provides Clues to the Mechanism of Remission of Inflammatory Diseases During Pregnancy
Analysis of pro- and anti-inflammatory cytokines in pregnant women with rheumatoid arthritis, juvenile idiopathic arthritis, and ankylosing spondylitis may help provide a better understanding as to why certain rheumatic diseases improve during pregnancy...Ostensen M, et al. Ann Rheum Dis. 2005;64:839-844
Tuesday May 17, 2005
Infliximab Approved for Treatment of Psoriatic Arthritis
Infliximab joins etanercept as an anti-TNF-α treatment option for patients with active psoriatic arthritis...FDA approves Remicade® for ninth indication: psoriatic arthritis [press release]. Malvern, Pa: Centocor, Inc; May 17, 2005.
Friday Apr 08, 2005
Thalidomide May Play a Role in Treatment of Refractory Radiculopathic Pain
Banned from use in the 1960s due to its teratogenic effects, thalidomide is being reexamined as a treatment for inflammatory and other types of disorders... Presented at the 24th Annual Scientific Meeting of the American Pain Society; March 30-April 2, 2005; Boston, Massachusetts
Friday Feb 18, 2005
Public Outcry Over Embattled Pain Relievers at FDA Advisory Panel Hearing
Some called for the withdrawal of all coxibs, while others pleaded for a return of the withdrawn rofecoxib (Vioxx) during public testimony at the FDA advisory meeting... US FDA Joint Meeting of the Arthritis Advisory Committee and the Drug Safety and Risk Management Advisory Committee; February 17, 2005.
Thursday Nov 04, 2004
Next generation COX-2 Inhibitor Arcoxia Receives FDA Approvable Letter
Final approval of etoricoxib must await FDA review of additional safety and efficacy data... Baraf HSB, et al. Presented at: Annual Meeting of the American College of Rheumatology; San Antonio, Tex.
Wednesday Nov 03, 2004
Merck Withdraws NDA for COX-2 Inhibitor Arcoxia
Just days after receiving an FDA "approvable letter", the company has withdrawn the new drug application for etoricoxib until additional safety and efficacy data are available...
Wednesday Oct 27, 2004
Anti-TNF Drugs Appear to Show Benefits in Most Ankylosing Spondylitis Patients and May Also Improve Psoriatic Arthritis
Recent study findings indicate that ankylosing spondylitis and psoriatic arthritis may respond well to infliximab, etanercept, and adalimumab... Rudwaleit M, Sieper J… Z Rheumatol. 2004;63:193-202.
Wednesday Oct 27, 2004
Anti-TNF Drugs Appear to Show Benefits in Most Ankylosing Spondylitis Patients – and May Also Improve Psoriatic Arthritis
Recent study findings indicate that ankylosing spondylitis and psoriatic arthritis may respond well to infliximab, etanercept, and adalimumab... Rudwaleit M, Sieper J… Z Rheumatol. 2004;63:193-202.
Friday Oct 22, 2004
Research Shows Benefits of TNF-α Blockers in Treating Ankylosing Spondylitis
Studies involving etanercept, infliximab, and adalimumab consistently show long-term benefits with regard to disease activity, function, and spinal mobility... Davis JC, et al. Presented at: Annual Meeting of the American College of Rheumatology; October 20, 2004; San Antonio, Tex.
Friday Oct 22, 2004
Research Shows Benefits of TNF-α Blockers in Treating Ankylosing Spondylitis
Studies involving etanercept, infliximab, and adalimumab consistently show long-term benefits with regard to disease activity, function, and spinal mobility... Davis JC, et al. Presented at: Annual Meeting of the American College of Rheumatology; October 20, 2004; San Antonio, Tex.
Thursday Oct 21, 2004
Researchers Outline Genetic and Environmental Triggers for Virulent Ankylosing Spondylitis
Genetic predisposition and a physically demanding job affect extent of disability that will accompany the inflammatory disease... Ward MM, et al. Presented at: Annual Meeting of the American College of Rheumatology; October 20, 2004; San Antonio, Tex.
Monday Oct 18, 2004
MRI Has Modest Predictive Value in Detecting Response to TNF Therapy in Ankylosing Spondylitis
Treatment responders had a higher activity index on MRI than did nonresponders, but the difference was less marked than investigators expected... Rudwaleit M, Listing J, Brandt J, Braun J October 18, 2004, Sieper J. Prediction of a major clinical response (BASDAI 50) to TNF-alpha blockers in ankylosing spondylitis. Ann Rheum Dis. 2004; 63:665-670.
Monday Oct 18, 2004
Key Contributors to Rheumatology Acknowledged in ACR 2004 Awards
The opening plenary session acknowledged the recipients of the Presidential Gold Medal, the Distinguished Investigator Award, and the Distinguished Rheumatologist Award.
|
